ReviewMedicina (Kaunas, Lithuania)2021
Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities.
Review in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Stage at Diagnosis and Molecular Subtype Distribution of Breast Cancer in Sub-Saharan Africa: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Unravelling novel microbial players in the breast tissue of TNBC patients: a meta-analytic perspective.NPJ biofilms and microbiomes · 2025Pooled it
- Association between NDRG1 protein expression and aggressive features of breast cancer: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- [Research square · 2026Article
- Differential expression of NEAT1 and miR-506-3p in triple-negative breast cancer: potential tissue-based diagnostic biomarkers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Spatiotemporal organisation of residual disease in mouse and human BRCA1-deficient mammary tumours and breast cancer.Nature communications · 2026Article
- Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia.Current oncology (Toronto, Ont.) · 2026Article
- New indole-linked 1,2,4-triazole derivatives as dual FAK inhibitors and apoptosis inducers targeting survival and migration in triple-negative breast cancer in-vitro.Scientific reports · 2026Article
- LHRH-Conjugated Magnetite Nanoparticles and Nanorods as Magnetic Resonance Imaging Contrast Agents for Targeting Triple-Negative Breast Cancer.Journal of functional biomaterials · 2026Article
- Integrated proteomics and metabolomics reveal phytosesquiterpene lactones inhibit TNBC cell activity by depleting ATP synthesis and reprogramming primary metabolism.Scientific reports · 2026Article
- A comparative analysis of mutational profiles between triple-negative breast cancer and non-triple-negative breast cancer.Discover oncology · 2026Article
- Diagnostic value of multimodal ultrasound imaging in triple-negative breast cancer.Frontiers in oncology · 2026Article
- A pilot study of multimodal MRI for the preoperative assessment of triple-negative breast cancer.Frontiers in oncology · 2026Article
- The Role of Angiogenesis in Breast Cancer and Obesity: Unravelling the Connection.International journal of breast cancer · 2026Review
- Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer.Pharmaceutics · 2025Review
- Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment.Nanomedicine (London, England) · 2025Review
- RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting mHereditas · 2025Article
- From Structure to Function: The Impact of EGFR and IGF-IR in 3D Breast Cancer Spheroids.Cancers · 2025Article
- Single-Cell Transcriptome Analysis Uncovers La Ribonucleoprotein 6 (LARP6) as a Dual Regulator of Proliferation and Immune Infiltration in Triple-Negative Breast Cancer.Journal of cellular and molecular medicine · 2025Article
- Estrogen receptor alpha dynamics and plasticity during endocrine resistance.Biology direct · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). It is a highly metastasized, heterogeneous disease that accounts for 10-15% of total breast cancer cases with a poor prognosis and high relapse rate within five years after treatment compared to non-TNBC cases. The diagnostic and subtyping of TNBC tumors are essential to determine the treatment alternatives and establish personalized, targeted medications for every TNBC individual. Currently, TNBC is diagnosed via a two-step procedure of imaging and immunohistochemistry (IHC), which are operator-dependent and potentially time-consuming. Therefore, there is a crucial need for the development of rapid and advanced technologies to enhance the diagnostic efficiency of TNBC. This review discusses the overview of breast cancer with emphasis on TNBC subtypes and the current diagnostic approaches of TNBC along with its challenges. Most importantly, we have presented several promising strategies that can be utilized as future TNBC diagnostic modalities and simultaneously enhance the efficacy of TNBC diagnostic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.